Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic mainstream.

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...